These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 15516860)

  • 1. Beta-blockers in heart failure: are pharmacological differences clinically important?
    Metra M; Cas LD; di Lenarda A; Poole-Wilson P
    Heart Fail Rev; 2004 Apr; 9(2):123-30. PubMed ID: 15516860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-blockade in heart failure: selective versus nonselective agents.
    Metra M; Nodari S; Dei Cas L
    Am J Cardiovasc Drugs; 2001; 1(1):3-14. PubMed ID: 14728047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of beta blockers in heart failure.
    Talbert RL
    Heart Fail Rev; 2004 Apr; 9(2):131-7. PubMed ID: 15516861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do beta-blockers prolong survival in heart failure only by inhibiting the beta1-receptor? A perspective on the results of the COMET trial.
    Packer M
    J Card Fail; 2003 Dec; 9(6):429-43. PubMed ID: 14966782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective or nonselective beta-adrenergic blockade in patients with congestive heart failure.
    Metra M; Nodari S; Boldi E; Dei Cas L
    Curr Cardiol Rep; 2000 May; 2(3):252-7. PubMed ID: 10980900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do pharmacological differences among beta-blockers affect their clinical efficacy in heart failure?
    Di Lenarda A; Sabbadini G; Sinagra G
    Cardiovasc Drugs Ther; 2004 Mar; 18(2):91-3. PubMed ID: 15293370
    [No Abstract]   [Full Text] [Related]  

  • 7. Beta-blockers in heart failure. The 'new wave' of clinical trials.
    Krum H
    Drugs; 1999 Aug; 58(2):203-10. PubMed ID: 10473016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics of beta-blockers in heart failure: lessons from the carvedilol or metoprolol European trial.
    Bauman JL; Talbert RL
    J Cardiovasc Pharmacol Ther; 2004 Jun; 9(2):117-28. PubMed ID: 15309248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carvedilol blocks beta2- more than beta1-adrenoceptors in human heart.
    Molenaar P; Christ T; Ravens U; Kaumann A
    Cardiovasc Res; 2006 Jan; 69(1):128-39. PubMed ID: 16225854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New and old beta-blockers in the treatment of heart failure].
    Metra M; Nodari S; Bignotti T; Gnesin P; Trussardi E; Cas LD
    Recenti Prog Med; 2002 Feb; 93(2):113-24. PubMed ID: 11887345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
    Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
    J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Commentary on the Carvedilol or Metoprolol European Trial (COMET).
    Poole-Wilson PA
    Am J Cardiol; 2004 May; 93(9A):40B-2B. PubMed ID: 15144936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term oral carvedilol in chronic heart failure.
    Di Lenarda A; Sabbadini G; Moretti M; Sinagra G
    Expert Opin Pharmacother; 2004 Jun; 5(6):1359-72. PubMed ID: 15163280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonselective versus selective beta-blockers in the management of chronic heart failure: clinical implications of the carvedilol or Metoprolol European Trial.
    Greenberg B
    Rev Cardiovasc Med; 2004; 5 Suppl 1():S10-7. PubMed ID: 15184835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial).
    Di Lenarda A; Remme WJ; Charlesworth A; Cleland JG; Lutiger B; Metra M; Komajda M; Torp-Pedersen C; Scherhag A; Swedberg K; Poole-Wilson PA;
    Eur J Heart Fail; 2005 Jun; 7(4):640-9. PubMed ID: 15921806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carvedilol in the treatment of chronic heart failure: lessons from the Carvedilol Or Metoprolol European Trial.
    Kveiborg B; Major-Petersen A; Christiansen B; Torp-Pedersen C
    Vasc Health Risk Manag; 2007; 3(1):31-7. PubMed ID: 17583173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET.
    Torp-Pedersen C; Poole-Wilson PA; Swedberg K; Cleland JG; Di Lenarda A; Hanrath P; Komajda M; Lutiger B; Metra M; Remme WJ; Scherhag A; Skene A;
    Am Heart J; 2005 Feb; 149(2):370-6. PubMed ID: 15846279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effects of carvedilol and metoprolol on regional vascular responses to adrenergic stimuli in normal subjects and patients with chronic heart failure.
    Hryniewicz K; Androne AS; Hudaihed A; Katz SD
    Circulation; 2003 Aug; 108(8):971-6. PubMed ID: 12912816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial.
    Zebrack JS; Munger M; Macgregor J; Lombardi WL; Stoddard GP; Gilbert EM
    Pharmacotherapy; 2009 Aug; 29(8):883-90. PubMed ID: 19637941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective versus nonselective beta-adrenergic receptor blockade in chronic heart failure: differential effects on myocardial energy substrate utilization.
    Al-Hesayen A; Azevedo ER; Floras JS; Hollingshead S; Lopaschuk GD; Parker JD
    Eur J Heart Fail; 2005 Jun; 7(4):618-23. PubMed ID: 15921803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.